Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Peginterferon Alfa-2a Maintenance in HIV/HCV Coinfection
NCT02762383Phase 3Terminated
- Sponsor
- Roche
- Start
- Mar 2005
- Primary completion
- Jun 2009
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfa-2a in hepatitis C (HCV), sponsored by Roche. Started Mar 2005; status: terminated.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02762383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762383.